Sometimes, all a stock needs to have a good day on Wall Street is a positive note from one of the analysts tracking it. This dynamic was in evidence on Thursday with QuidelOrtho (NASDAQ: QDEL), when a prognosticator's recommendation upgrade powered the in vitro diagnostic healthcare company's shares to a more than 10% gain. That made it quite the outperformer, as the S&P 500 index sagged by 0.3% Thursday.

A new bull arrives

Craig-Hallum's Bill Bonello was the day's newly minted QuidelOrtho bull. The analyst now feels the stock is a buy, one peg up from his previous hold rating. Bonello also substantially raised his price target on the shares to $57 from his previous target of $40.

The modifications stem from the analyst's belief that QuidelOrtho has vast and unexploited potential to boost its fundamentals. Bonello went so far as to write in his latest analyst note on the company that it should be able to grow revenue at mid-to-high single-digit percentage rates by 2027. Better still, in his view, it could crank its earnings before interest, taxes, depreciation, and amortization (EBITDA) margins into the mid-to-high 20% range.

"With comparable companies trading at 12 to 14 times forward year EBITDA, it is conceivable that QDEL shares could reach $100 or more, two years from now," he wrote.

Bottom-line concerns

On such a basis, QuidelOrtho does seem to be undervalued. However, the company has booked net losses in four of its five most recently reported quarters, a trend that is surely keeping some investors away. It might have to book a few profitable frames in order to regain the market's trust.

Should you invest $1,000 in QuidelOrtho right now?

Before you buy stock in QuidelOrtho, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and QuidelOrtho wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $650,810!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of September 3, 2024

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends QuidelOrtho. The Motley Fool has a disclosure policy.

Why QuidelOrtho Stock Blasted 10% Higher Today was originally published by The Motley Fool